Cabo's HR is better than I anticipated. I really gotta wonder if the FDA tipped them off to an approval in April. EXEL has been saying they would be ready to go in April for months. Now they have a month or so to brag about their superior HR and p value compared to Nivo AND they get to present the data at ASCO.
In the year end/4th quarter conference call Evercore analyst Mark Schoenbaum noted that a patient in the hemophilia gene therapy clinical trial had a blog. I assume the patient is blogging about their experience on the clinical trial. Has anyone on this board been able to find the link to that patient blog???